This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Aetna And Fresenius Medical Care Begin Chronic Kidney Disease Management Program

Stocks in this article: AET FMS

Aetna (NYSE: AET) and Fresenius Medical Care (NYSE: FMS) today announced the launch of a joint program aimed at improving clinical outcomes and reducing costs by slowing the progression of chronic kidney disease in members and facilitating gentler, less costly transitions to dialysis or pre-transplant care.

Chronic kidney disease is the slow loss of kidney function over time and is often caused by diabetes or high blood pressure. The new patient-centric care program enhances coordination of care among specialists, primary care providers and nurses. Together, they identify members at risk and improve clinical management in earlier stages of kidney disease to help slow the progression to kidney failure. An important component of the program involves daily communication of the member’s biometric and health status through a wireless communication device that helps the care team identify, address or even prevent potentially serious complications.

"We believe the model will improve our members' quality of life by helping them and their doctors better manage the conditions contributing to or resulting from chronic kidney disease. If dialysis becomes necessary we want to help members begin dialysis with the lowest risk for complications,” says Roger London, M.D., Aetna’s Northeast Region medical director.

Often people do not know they have chronic kidney disease because the kidneys may slowly stop working over 10 - 20 years before end-stage disease -- kidney failure – results. Kidney failure often involves an abrupt hospitalization to control complications and to start dialysis. Better coordination, education, planning and awareness of dialysis options provided through the program can help members begin dialysis treatment on a safer, less costly outpatient basis .

A track-record of success

The program is modeled on Fresenius Health Partners’ successful five-year demonstration project with Medicare beneficiaries on dialysis. Concluded last year with the U.S. Centers for Medicare & Medicaid Services (CMS), the project resulted in health care costs 12 percent below the Medicare Advantage and four percent below the Medicare fee-for-service benchmarks for this population. At the same time patients in the program experienced overall improvement in clinical measures including a 24 percent improvement in the rate of mortality and a 20 percent reduction in all-cause hospitalization versus national benchmarks.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs